


Figure S6

Supplementary Figure S6. Epacadostat hampers AML progression. Related to Figure 6. (A) Kyn/Trp ratio levels in WT mice injected or not with MLL/AF9 cells and treated with either vehicle or epacadostat (no leukemia: vehicle n=9, Epac. n=9; MLL/AF9-injected mice: vehicle n=18, Epac. n=14). One-way ANOVA. (B) Survival curve comparing leukemic mice treated with either vehicle (n=19) or epacadostat (n=19); Kaplan-Meier curve with p-value of log rank (Mantel-Cox) test. (C) *In vivo* leukemia burden quantification of mice shown in (A), treated with either vehicle or 0.8g/kg epacadostat. (D) Kyn and Trp absolute levels and Kyn/Trp ratio in serum of WT mice injected with MLL/AF9 cells and treated with either vehicle (n=6) or 1.6g/kg *ad libitum* epacadostat diet (n=9). (E) *In vivo* leukemia burden quantification of mice in (D). (F) Kyn and Trp absolute levels in serum of NSGS mice transplanted with either healthy CD34⁺ cells (n=11) or patient-derived AML cells (n=27). (G) Multiple variable data plot of SAA3, Kyn/Trp ratio serum levels and transplanted disease in NSGS mice transplanted with CD34⁺ healthy cells (n=11) or with patient-derived AML cells (n=27), Pearson correlation values are shown for Kyn/Trp ratio and SAA3 serum levels. (H) AML burden in BM aspirates from PDX in NSGS mice at randomization (3weeks; n=8 vehicle, n=10 epacadostat). (I) Kyn and Trp levels in serum of PDX mice at harvest 5 weeks after transplant and 12 days post-epacadostat treatment (n=8 vehicle, n=10 epacadostat). (J) AML burden in BM aspiration 8 weeks after transplant of PDX NSG mice at randomization (n=5 for all groups). (K) Kyn/Trp ratio serum levels in all mice before treatment (n=20) and after 3 weeks of epacadostat diet (n=7). All data expressed as mean ± SEM. Statistical analysis was done with unpaired t-test unless otherwise stated.